BCAL DIAGNOSTICS LIMITED — Capital/Financing Update 2026

Mar 30, 2026

==> picture [152 x 46] intentionally omitted <==

ASX Announcement

31 March 2026

==> picture [182 x 47] intentionally omitted <==

BCAL submits MSAC application for Avantect Pancreatic Cancer early detection blood test

Highlights

• Application submitted to Medical Services Advisory Committee (MSAC) seeking Medicare Benefits Schedule (MBS) reimbursement for Avantect Pancreatic Cancer Test.

• Commercial rollout underway with availability across NSW, QLD and Victoria via Sonic Healthcare and nationally through Healius.

• Strong early clinician and market engagement following January 2026 launch.

• Clinical evidence base and advocacy support underpin reimbursement submission.

BCAL Diagnostics Limited (ASX: BDX), an Australian healthcare company pioneering diagnostics for early detection of cancer, has applied to the Medical Services Advisory Committee (MSAC) seeking public reimbursement under the Medicare Benefits Schedule (MBS) for its Avantect® Pancreatic Cancer Test.

The Avantect® test is a non-invasive, blood-based assay that uses cell-free DNA (cfDNA) epigenomic profiling to support earlier detection of pancreatic cancer in high-risk populations. These include individuals aged 50 years and older with new-onset diabetes, as well as those with known genetic or familial risk factors.

Pancreatic cancer remains one of the most lethal malignancies, largely due to late-stage diagnosis. There is currently no established standard-of-care screening pathway for early detection in at-risk individuals. Avantect® is designed to complement existing clinical pathways by identifying patients who may benefit from earlier imaging and specialist referral.

BCAL launched the Avantect Pancreatic blood test in Syndey in January 2026. The test is now available through selected Sonic Healthcare pathology collection centres in New South Wales, Queensland and Victoria, and nationally through Healius Pathology Network.

Early market feedback indicates strong interest from clinicians, particularly in endocrinology and primary care settings managing patients with new-onset diabetes. This initial uptake supports BCAL’s strategy to drive broader adoption through reimbursement and integration into routine clinical workflows.

BCAL CEO Shane Ryan said, “The submission to MSAC represents a critical milestone in our strategy to establish Avantect® as a reimbursed, standard-of-care diagnostic for pancreatic cancer risk assessment. Securing MBS reimbursement has the potential to significantly accelerate adoption, improve access for patients, and position BCAL at the forefront of early cancer detection in Australia.

==> picture [152 x 46] intentionally omitted <==

“We are encouraged by the strong clinical interest since launch and the support from the medical and patient advocacy communities, and we look forward to progressing through the MSAC evaluation process.”

The MSAC is an independent expert committee that evaluates new medical technologies and diagnostics to determine whether they should be publicly funded under the MBS. The assessment process is rigorous and evidence-based, typically involving:

• Evaluation of clinical effectiveness and safety

• Assessment of cost-effectiveness and budget impact

• Review of comparative benefit versus existing standard of care

• Consideration of patient outcomes and system-wide healthcare value

A positive MSAC recommendation is required for the Australian Government to consider listing a test on the MBS. If successful, MBS reimbursement would be a significant commercial inflection point for BCAL, enabling:

• Broader patient access through subsidised testing

• Increased clinician adoption driven by reduced out-of-pocket cost barriers

• Scaled national use and revenue growth

• Integration into standard clinical practice guidelines over time

The MSAC submission is supported by a growing body of clinical evidence demonstrating the test’s performance in detecting pancreatic cancer in at-risk populations. This includes validation studies underpinning the assay’s sensitivity and specificity in real-world clinical settings.

The application is further strengthened by engagement with leading pancreatic cancer advocacy organisations, including PanCare Foundation and Pankind. These groups have played an important role in highlighting the urgent unmet need for earlier detection and improved patient outcomes.

BCAL will provide further updates as the MSAC assessment process progresses.

This announcement has been approved for release by the Board of BCAL.

ENDS

For further information:

Shane Ryan Jayne Shaw Chief Executive Officer Executive Chair Sryan@bcaldiagnostics.com Jshaw@bcaldiagnostics.com

==> picture [152 x 46] intentionally omitted <==

About BCAL Diagnostics

BCAL is an Australian health care company engaged in early cancer detection. BCAL launched its first test BREASTEST plus ™ as a ‘rule-out’ test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTEST plus ™ is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women.

BCAL holds exclusive license with ClearNote Health Inc., a US-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand. For more information, visit earlydetection.com.au

BCAL is headquartered in Sydney, Australia and listed on the Australian Securities Exchange (ASX: BDX). For more information: htps://www.bcaldiagnostcs.com/ or contact info@bcaldiagnostcs.com